TY - JOUR
T1 - The DAHANCA 32 study
T2 - Electrochemotherapy for recurrent mucosal head and neck cancer
AU - Plaschke, Christina Caroline
AU - Johannesen, Helle Hjorth
AU - Hansen, Rasmus Hvass
AU - Hendel, Helle Westergren
AU - Kiss, Katalin
AU - Gehl, Julie
AU - Wessel, Irene
PY - 2019/2
Y1 - 2019/2
N2 - Background: Electrochemotherapy is an established treatment for cutaneous tumors. This study aimed at determining efficacy of electrochemotherapy in recurrent head and neck cancer. Methods: Phase II clinical trial in patients with recurrent head and neck carcinomas with no curative treatment options. Electrochemotherapy was performed under general anesthesia. Primary endpoint was tumor response (CT scanning) evaluated at week 8. Secondary endpoints included biopsy results, MRI and fluorodeoxyglucose-positron emission tomography scanning, safety, toxicity, pain score, and quality-of-life questionnaires. Results: Of 26 patients treated, 5 (19%) achieved complete response, 10 (39%) partial response, resulting in an objective response of 58%. Two responders remain without recurrence. No serious adverse events occurred during treatment. Four events occurred posttreatment: one bleeding episode, two episodes with mucosal swelling, and one patient died due to disease progression. Conclusion: Electrochemotherapy is efficient against local recurrence of head and neck cancer with an overall response rate of 58%.
AB - Background: Electrochemotherapy is an established treatment for cutaneous tumors. This study aimed at determining efficacy of electrochemotherapy in recurrent head and neck cancer. Methods: Phase II clinical trial in patients with recurrent head and neck carcinomas with no curative treatment options. Electrochemotherapy was performed under general anesthesia. Primary endpoint was tumor response (CT scanning) evaluated at week 8. Secondary endpoints included biopsy results, MRI and fluorodeoxyglucose-positron emission tomography scanning, safety, toxicity, pain score, and quality-of-life questionnaires. Results: Of 26 patients treated, 5 (19%) achieved complete response, 10 (39%) partial response, resulting in an objective response of 58%. Two responders remain without recurrence. No serious adverse events occurred during treatment. Four events occurred posttreatment: one bleeding episode, two episodes with mucosal swelling, and one patient died due to disease progression. Conclusion: Electrochemotherapy is efficient against local recurrence of head and neck cancer with an overall response rate of 58%.
KW - bleomycin
KW - electrochemotherapy
KW - electroporation
KW - head and neck cancer
KW - quality-of-life
U2 - 10.1002/hed.25454
DO - 10.1002/hed.25454
M3 - Journal article
C2 - 30552847
AN - SCOPUS:85058397536
SN - 1043-3074
VL - 41
SP - 329
EP - 339
JO - Head & Neck (Print Edition)
JF - Head & Neck (Print Edition)
IS - 2
ER -
